Subscription form | EBVALLO

ALLELE PUBLICATION NOW AVAILABLE

"Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy
(ALLELE): a phase 3, multicentre, open-label trial"

Mahadeo, K.M et al. Lancet Oncology, January 2024

Please enter your email address to receive the ALLELE publication:

Email address *

Country

By clicking on send - I accept to receive future information on hematological malignancies from Pierre Fabre Medicament.

Your email address will be conserved for 5 years after our latest interaction. If you want more information about data processing, please consult our Privacy Policy.

* Required field

CAPTCHA

EU Healthcare Professionals

This is an international website for EBVALLO® dedicated to healthcare professionals (outside the UK and ROI).

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that:

I am a healthcare professional inside the EU (outside the UK and ROI) and I have read the information above, the Legal Notice and the Privacy Policy

Patients/Non EU Healthcare Professionals

This is an international website for EBVALLO® dedicated to healthcare professionals (outside the UK and ROI).

I am a patient or a healthcare professional outside the EU.

References

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

1. Mahadeo, K.M. et al. (2024). Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr viruspositive post-transplant lymphoproliferative disease after failure of Rituximab or rituximab and chemotherapy (allele): A phase 3, Multicentre,
open-label trial. The Lancet Oncology, January 2024.
2. EBVALLO Summary of Product Characteristics.
3. Dierickx D, et al. Post-Transplantation Lymphoproliferative Disorders in Adults. N Engl J Med. 2018;378:549–562.
4. Nijland ML, et al. Epstein-Barr virus-positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management. Transplant Direct. 2016;2(1):e48.
5. Sanz J, et al. Abstract 1454. Presented at: ASH Annual Meeting and Exposition; December 11–14, 2021; Atlanta. Clinical Outcomes of Patients with Epstein–Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab:A Multinational, Retrospective Chart Review Study. Blood. 2021;138(Suppl 1):1454.
6. Dharnidharka V, et al. Abstract 2528. Presented at: ASH Annual Meeting and Exposition; December 11–14, 2021; Atlanta. Clinical Outcomes of Solid Organ Transplant Patients with Epstein-Barr Virus-Driven (EBV) Post-Transplant Lymphoproliferative Disorder (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study. Blood. 2021;138(Suppl 1):2528.
7. EBVALLO EPAR.

This is an international website for EBVALLO®. IMPORTANT: This material was developped in compliance with EFPIA code and EBVALLO EU SmPC. Registration conditions and prescribing information may vary per country. Therefore, before prescribing any product, Health Care Providers must refer to their country's prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

Last update: 04/2024